OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.52 EUR -6.28%
Market Cap: 123.4m EUR

Net Margin
OSE Immunotherapeutics SA

44.9%
Current
-268%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
44.9%
=
Net Income
37.4m
/
Revenue
83.4m

Net Margin Across Competitors

OSE Immunotherapeutics SA
Glance View

Market Cap
120.9m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
4.7 EUR
Overvaluation 15%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
44.9%
=
Net Income
37.4m
/
Revenue
83.4m
What is the Net Margin of OSE Immunotherapeutics SA?

Based on OSE Immunotherapeutics SA's most recent financial statements, the company has Net Margin of 44.9%.

Back to Top